| pubmed-article:12168814 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12168814 | lifeskim:mentions | umls-concept:C0678222 | lld:lifeskim |
| pubmed-article:12168814 | lifeskim:mentions | umls-concept:C1518174 | lld:lifeskim |
| pubmed-article:12168814 | lifeskim:mentions | umls-concept:C0039286 | lld:lifeskim |
| pubmed-article:12168814 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:12168814 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12168814 | pubmed:dateCreated | 2002-8-9 | lld:pubmed |
| pubmed-article:12168814 | pubmed:abstractText | Selective estrogen receptor modifiers (SERMs) are used chronically in the treatment of breast cancer and osteoporosis but some patients become resistant, at which point second-line SERMs are considered as options. Because the use of SERMs is increasing and breast cancer is so common, we tested the hypothesis that treatment with SERMs can induce cross-resistance to other SERMs. We used three cultured breast carcinoma cell lines (MCF-7, ZR-75-1, and T47D) which are estrogen-receptor-positive (ER+) and are prone to developing resistance to hormonal treatment. Cell lines were exposed to increasing doses of raloxifene. Raloxifene-resistant clones were selected and tested for cross-resistance to tamoxifen. Compared to untreated cells, raloxifene-resistant clones showed an increased IC50 (reduced potency) of about 15,000-fold with no apparent change in maximal inhibition of cell growth. These same raloxifene-resistant clones were also about 15-fold more resistant to the growth-inhibiting effects of tamoxifen. While the resistance to tamoxifen is considerably less marked (1000-fold less), it is large enough to raise the question as to whether patients who become resistant to raloxifene will benefit by switching to tamoxifen or vice versa. | lld:pubmed |
| pubmed-article:12168814 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12168814 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12168814 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12168814 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12168814 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12168814 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12168814 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12168814 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12168814 | pubmed:issn | 0250-7005 | lld:pubmed |
| pubmed-article:12168814 | pubmed:author | pubmed-author:BomanB MBM | lld:pubmed |
| pubmed-article:12168814 | pubmed:author | pubmed-author:FanY SYS | lld:pubmed |
| pubmed-article:12168814 | pubmed:author | pubmed-author:FieldsJ ZJZ | lld:pubmed |
| pubmed-article:12168814 | pubmed:author | pubmed-author:TamE WEW | lld:pubmed |
| pubmed-article:12168814 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12168814 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:12168814 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12168814 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12168814 | pubmed:pagination | 1379-83 | lld:pubmed |
| pubmed-article:12168814 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:meshHeading | pubmed-meshheading:12168814... | lld:pubmed |
| pubmed-article:12168814 | pubmed:articleTitle | Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells. | lld:pubmed |
| pubmed-article:12168814 | pubmed:affiliation | Division of Genetic and Preventive Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA. | lld:pubmed |
| pubmed-article:12168814 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12168814 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
